Codexis, Inc. (CDXS) Q1 2026 Earnings Call Transcript

Codexis, Inc. (CDXS) Q1 2026 Earnings Call Transcript

Seeking Alpha • May 8, 2026

Codexis Reports First Quarter 2026 Financial Results

Reports revenue of $15.2 million for the first quarter, company reiterates full-year financial guidance Three presentations at upcoming TIDES USA annual meeting to feature new data for ECO Synthesis manufacturing platform capabilities REDWOOD CITY, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex therapeutics, today announced financial results for the first quarter ended March 31, 2026, and provided a business update.

GlobeNewsWire • May 7, 2026

Codexis (CDXS) Reports Q1 Loss, Beats Revenue Estimates

Codexis (CDXS) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to a loss of $0.25 per share a year ago.

Zacks Investment Research • May 8, 2026

Codexis (CDXS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

Codexis (CDXS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • Apr 30, 2026

Codexis to share RNA manufacturing advances at TIDES USA

REDWOOD CITY, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS) a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, will present new data on ECO Synthesis® Manufacturing Platform and provide an update on regulatory engagement for its enzymatic platform at TIDES USA, held May 11–14 at the Hynes Convention Center in Boston.

GlobeNewsWire • Apr 29, 2026

Codexis Posts Strong Q4, Eyes siRNA Market With ECO Synthesis Platform

Codexis, Inc. delivered strong FY25 results, with revenue up 19% to $70.4M, driven by a $37.8M technology transfer agreement with Merck. CDXS's ECO Synthesis platform targets the expanding siRNA/RNA therapeutics market, offering scalable, high-margin enzymatic manufacturing as a disruptive alternative to chemical synthesis. Operational improvements included gross margin expansion to 64%, narrowed net loss, and SG&A expense reductions, positioning CDXS for financial sustainability.

Seeking Alpha • Mar 12, 2026

Codexis, Inc. (CDXS) Q4 2025 Earnings Call Transcript

Codexis, Inc. (CDXS) Q4 2025 Earnings Call Transcript

Seeking Alpha • Mar 11, 2026

Codexis Reports Fourth Quarter and Fiscal Year 2025 Financial Results

Q4 revenue of $38.9 million, total revenue of $70.4 million for the fiscal year ended December 31, 2025 Ended year with $78.2 million in cash, cash equivalents and short-term investments, runway through 2027 Completed $37.8 million Technology Transfer Agreement with Merck REDWOOD CITY, Calif., March 11, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex therapeutics, today announced financial results for the fourth quarter and year ended December 31, 2025, and provided a business update.

GlobeNewsWire • Mar 11, 2026

Codexis (CDXS) Beats Q4 Earnings and Revenue Estimates

Codexis (CDXS) came out with quarterly earnings of $0.11 per share, beating the Zacks Consensus Estimate of $0.01 per share. This compares to a loss of $0.13 per share a year ago.

Zacks Investment Research • Mar 11, 2026

Codexis signs agreement to manufacture 50 g siRNA using its ECO Synthesis® Manufacturing Platform

REDWOOD CITY, Calif., March 4, 2026 /PRNewswire/ -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced it has entered into an agreement with an innovator pharmaceutical company to manufacture 50 grams of small interfering RNA (siRNA) using its proprietary ECO Synthesis manufacturing platform to support preclinical development of a therapeutic candidate targeting a cardiovascular indication.

PRNewsWire • Mar 4, 2026